Jim Cramer Praises Johnson & Johnson (JNJ)'s Drugs

We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed.

Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer was nothing but enthused about the spinoff. He believes that the spinoff would enable Johnson & Johnson (NYSE:JNJ) to position itself to become a growth stock to compete with Eli Lilly. In this appearance, he discussed the firm’s drug portfolio for mental health conditions:

“Two hours ago the FDA approved Caplyta for major depressive disorder. There’s been nothing for this of any substance. This is fantastic news. You may have seen when you’re watching football last week, ads for Caplyta. And it’s done by Intra-Cellular, but that’s actually a company that JNJ bought. JNJ’s been pioneering work on suicide with Spravato and now they’re doing pioneering work on major depressive disorder. They are tackling things that no one else even wants to go after, congratulations, a major win, and it will be, substative and additive to earnings.”

While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.